ThromboGenics reports Phase I/II data for DME candidate

ThromboGenics N.V. (Euronext:THR) said THR-317 was well tolerated with no dose-limiting toxicities (DLTs) reported in the Phase I/II THR-001 trial to treat diabetic macular edema (DME).

The single-blind, European trial enrolled 49 DME patients, including 40 anti-VEGF treatment-naïve patients and nine suboptimal anti-VEGF responders, to receive three intravitreal injections of 4 or 8 mg THR-317 given about one month apart...